Norda Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Norda's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | 20.9% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Norda makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 128 | 100 | 1 | 0 |
| 31 Dec 21 | 139 | 82 | 1 | 0 |
| 31 Dec 20 | 469 | 428 | 1 | 0 |
| 31 Dec 19 | 84 | 40 | 1 | 0 |
| 31 Dec 18 | 17 | -107 | 1 | 0 |
| 31 Dec 17 | 62 | 23 | 1 | 0 |
| 31 Dec 16 | 76 | 59 | 1 | 0 |
| 31 Dec 15 | 39 | 26 | 1 | 0 |
| 31 Dec 14 | 0 | 14 | 1 | 0 |
| 31 Dec 13 | 0 | 12 | 1 | 0 |
Quality Earnings: Insufficient data to determine if NORD has high quality earnings.
Growing Profit Margin: Insufficient data to determine if NORD's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NORD's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare NORD's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if NORD's earnings growth over the past year exceeded the Biotechs industry average.
Return on Equity
High ROE: NORD has a negative Return on Equity (0%), as it is currently unprofitable.